Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

13 Nov 2024

Abstract excerpt

ABSTRACT: The International Consensus (ICC) and World Health Organization fifth edition (WHO5) classifications introduced new, but differing, categories of myeloid disease defined by TP53 mutations. We reviewed a cohort of 188 cases of TP53-mutated myeloid disease to determine how diagnoses and outcomes differ between the 2 classifications. Overall, 120 (64%) cases were classified differently by the ICC and WHO5,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39536285
DOI: 10.1182/bloodadvances.2024014140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classificationsPMID 39536285Read ↗

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortSemantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrationsSemantic proximity Read ↗

Acute Myeloid Leukemia and Myelodysplastic Neoplasms: Clinical Implications of Myelodysplasia-Related Genes Mutations and TP53 AberrationsSemantic proximity Read ↗

Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Implications of the 5th Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia.Semantic proximity Read ↗

The International Consensus Classification of acute myeloid leukemia.Semantic proximity Read ↗

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.Semantic proximity Read ↗

Myeloid neoplasms in the World Health Organization 2016 classification.Semantic proximity Read ↗

The International Consensus Classification of myelodysplastic syndromes and related entities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.